What is PFAS and why does it represent such a large liability for 3M?

PFAS (per- and polyfluoroalkyl substances) are a class of man-made chemicals used since the 1940s in products like non-stick cookware coatings, water-resistant clothing, food packaging, and firefighting foam (AFFF). PFAS are nicknamed 'forever chemicals' because they do not break down naturally in the environment or human body. 3M was a major PFAS manufacturer for decades, producing them under the Scotchgard brand and for AFFF firefighting foam used at military bases and airports. PFAS contamination has been detected in drinking water supplies near manufacturing sites, military bases, and airports across the U.S. 3M settled with U.S. public water utilities for $10.3B in 2023; additional liabilities related to contaminated sites, private lawsuits, and PFAS in products (versus water contamination) remain ongoing and unresolved.

What is Solventum and why did 3M spin it off?

Solventum is the name of the healthcare business that 3M spun off in April 2024 as an independent publicly traded company. Solventum's businesses include: MedSurg (surgical drapes, sterilization monitoring, wound care); Dental (3M ESPE oral care products used in dentistry); Health Information Systems (medical coding and claims management software); and Separation and Purification Sciences (filtration for biopharma manufacturing). 3M spun off Solventum for several reasons: the healthcare business had different growth drivers, customer relationships, and capital needs than 3M's industrial businesses; separating it allows each company to focus on its core markets; and the separation was intended to unlock shareholder value by eliminating the 'conglomerate discount' applied to 3M's diversified portfolio by investors.

What is contract sterilization and why does STERIS dominate it?

Contract sterilization is a service where medical device manufacturers outsource the sterilization of their products (syringes, catheters, surgical kits, implants) to a specialized facility rather than building their own sterilization infrastructure. Medical devices must be sterile when they leave the manufacturing facility; sterilizing them in-house requires expensive, regulated equipment and compliance expertise. Contract sterilizers like STERIS's AST division provide economies of scale, regulatory expertise, and proven sterilization validation — essential for FDA regulatory submissions. The contract sterilization market has high barriers to entry: facilities must obtain EPA permits for ethylene oxide (the most common sterilization method); FDA registration and ongoing compliance are required; and sterilization validation for each device type takes months and significant cost. Once a device manufacturer has validated a specific contract sterilizer's process, switching requires re-validation — creating high switching costs that benefit STERIS's incumbency.

Data as of: June 17, 2026

brimindinvest.com / compare / ste-vs-mmm-medicalLIVE

STE

STERIS plc · Healthcare - Medical Devices & Sterilization

N/A

N/A this month

VERSUS

COMPARE

MMM

3M Company · Industrials - Diversified Industrial & Healthcare

N/A

N/A this month

Comparison scoreboard

MIXED SETUP

AI Scorei

STE N/A

MMM N/A

1Y Returni

STE N/A

MMM N/A

Fwd P/Ei

STE N/A

MMM N/A

Target Up.i

STE N/A

MMM N/A

Op. Margini

STE N/A

MMM N/A

Quick take

STE vs MMM Stock Comparison: AI Score, Valuation, Performance and Upside

ShareX LinkedIn Reddit Facebook WhatsApp

STE (STERIS) and MMM (3M) are both healthcare-adjacent companies but with very different focuses — STERIS is a pure-play infection prevention and sterile processing company with mission-critical hospital infrastructure, while 3M is a highly diversified industrial conglomerate managing major legal liabilities (PFAS, Combat Arms) and a strategic transformation that included spinning off its healthcare segment as Solventum. STERIS is the focused healthcare infrastructure play; 3M is the industrial conglomerate in transformation.

STE vs MMM is mission-critical sterile processing infrastructure (STERIS's non-discretionary hospital sterilization services and equipment with high switching costs and recurring consumables) versus diversified industrial conglomerate managing litigation and transformation (3M's broad industrial portfolio under pressure from PFAS and earplug liabilities while spinning off healthcare) — focused healthcare infrastructure specialist versus industrial conglomerate in restructuring.

Want a full valuation workup? 46-section report — AI Score, Monte Carlo forecast, bull/bear case, DCF, and more.

MMM Report

Normalized 1Y performance

STE

MMM

Not enough data to chart yet.

Recent returns

STE

MMM

Not enough data to chart yet.

Analyst price targets & sentiment

Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.

STE

Price target data unavailable

N/A

MMM

Price target data unavailable

N/A

Who should consider this stock?

STE may suit investors who:

Want a high-quality, mission-critical medical infrastructure company with non-discretionary hospital sterile processing revenue that is not dependent on elective procedure volumes or drug development funding
Value STERIS's mix of capital equipment and recurring consumables/service revenue as providing stability — the consumables and service segment cushions capital equipment cycle variability
Prefer a focused infection prevention and sterile processing pure-play over diversified conglomerates with unrelated business segments and legacy liabilities

MMM may suit investors who:

Want a high-dividend industrial conglomerate with a large global distribution network and iconic brands — 3M has paid dividends for over 60 consecutive years and has significant cash generation despite legal headwinds
Value 3M's diversification across industrial, safety, and technology markets as providing revenue resilience across different economic sectors
Are comfortable with the PFAS and earplug litigation risk as manageable given the settlement frameworks in place, and see 3M's post-Solventum industrial focus as a potential catalyst for valuation re-rating

Performance & AI score

Performance & AI score
Metric	STE	MMM
AI scorei	N/A	N/A
AI ranki	N/A	N/A
Latest closei	N/A	N/A

Valuation & upside potential

Valuation & upside potential
Metric	STE	MMM
Market capi	N/A	N/A
Trailing P/Ei	N/A	N/A
Forward P/Ei	N/A	N/A
Price/Salesi	N/A	N/A
EV/Revenuei	N/A	N/A
Analyst targeti	N/A	N/A
Target upsidei	N/A	N/A

Full DCF model for MMM

Growth, profitability & risk

Growth, profitability & risk
Metric	STE	MMM
Revenue growthi	N/A	N/A
Earnings growthi	N/A	N/A
EPS growthi	N/A	N/A
FCF margini	N/A	N/A
Operating margini	N/A	N/A
Profit margini	N/A	N/A
ROIC proxyi	N/A	N/A
Return on equityi	N/A	N/A
Dividend yieldi	N/A	N/A
Payout ratioi	N/A	N/A
Dividend growth streaki	N/A	N/A
Betai	N/A	N/A
Debt/equityi	N/A	N/A
Current ratioi	N/A	N/A
Quick ratioi	N/A	N/A

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

STE max drawdowniN/A

MMM max drawdowniN/A

STE max wkly dropiN/A

MMM max wkly dropiN/A

5Y risk snapshot

STE max drawdowniN/A

MMM max drawdowniN/A

STE max wkly dropiN/A

MMM max wkly dropiN/A

10Y risk snapshot

STE max drawdowniN/A

MMM max drawdowniN/A

STE max wkly dropiN/A

MMM max wkly dropiN/A

Performance metrics by period

Performance metrics by period
Period	Metric	STE	MMM
1Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
5Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
10Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A

AI Prediction Signali

Members only

Next 5 trading days

STE

+2.8%BUY

MMM

+1.1%HOLD

Next 30 trading days

STE

+6.4%BUY

MMM

+3.2%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Business comparison

Business comparison
Category	STE	MMM
Company	STERIS plc	3M Company
Sector	Healthcare - Medical Devices & Sterilization	Industrials - Diversified Industrial & Healthcare
Industry	N/A	N/A
Core business	STERIS is a global leader in infection prevention and sterile processing — providing sterilizers and reprocessing equipment for surgical instruments, endoscopes, and medical devices used in hospitals; sterilization services for medical device manufacturers (contract sterilization using ethylene oxide and other modalities); and consumables (detergents, indicators, wrapping) used in hospital central sterile departments. STERIS also provides surgical tables and lighting, patient safety monitoring, and outsourced sterile processing services.	3M is a global diversified industrial company producing thousands of products across safety and industrial (respirators, abrasives, adhesives), transportation and electronics (films, electrical products), and healthcare (wound care, surgical drapes, oral care, infection prevention). 3M has been undertaking a strategic transformation: spinning off its healthcare business as Solventum in 2024 and managing significant liabilities from PFAS contamination and Combat Arms Earplugs litigation.
Investor focus	Investors track STERIS's Healthcare segment (hospital sterile processing equipment and services), Applied Sterilization Technologies segment (contract sterilization for medical device manufacturers), and Life Sciences segment (pharmaceutical manufacturing sterility), as well as recurring consumables and service revenue versus capital equipment cycles.	Investors track 3M's Safety & Industrial and Transportation & Electronics segment revenues after the Solventum healthcare spinoff, PFAS settlement progress and financial impact, Combat Arms earplug litigation resolution, organic revenue growth ex-divested businesses, and the company's path to deleveraging after legal settlements.

STE strengths

Mission-critical sterile processing infrastructure — every hospital that performs surgery requires sterilization of surgical instruments; this is non-discretionary, regulated hospital infrastructure where STERIS's equipment and processes are deeply embedded
Recurring consumables and service revenue — STERIS's installed base of sterilizers generates ongoing consumable (indicator tape, sterilization wraps, detergents) and service contract revenue that provides revenue stability beyond capital equipment cycles
Contract sterilization competitive moat — STERIS's Applied Sterilization Technologies (contract sterilization for medical device manufacturers) has high barriers to entry due to EPA and FDA regulations, specialized equipment, and established relationships with device companies that depend on reliable sterilization services

MMM strengths

Global distribution and brand recognition across industrial and consumer channels — 3M's distribution relationships and brand trust (Post-it, Scotch, Nexcare) provide access to virtually every industrial and consumer market globally
Innovation infrastructure spanning multiple technology platforms — 3M's investment in adhesives, films, abrasives, and materials science creates proprietary technologies applicable across many industries and products
Post-healthcare-spinoff focus on industrial and safety markets — after spinning off Solventum, 3M can focus capital allocation on its core industrial and safety businesses

Risks to watch — STE

Capital equipment spending cycles — hospital capital budgets affect STERIS's equipment revenue; hospital system consolidation, reimbursement pressures, or economic stress can delay equipment replacement cycles
EtO (ethylene oxide) regulatory risk — ethylene oxide is the most common gas sterilization method but is also a carcinogen; EPA regulations on EtO emissions are tightening, potentially requiring capital investments in emission controls or affecting STERIS's contract sterilization operations
Integration of Cantel Medical acquisition — STERIS acquired Cantel Medical (endoscope reprocessing specialist) in 2021; integration adds scale but introduces complexity

Risks to watch — MMM

PFAS (per- and polyfluoroalkyl substances) liability — 3M manufactured PFAS chemicals for decades; environmental contamination lawsuits have resulted in a $10.3B settlement with U.S. public water utilities with more potential liability outstanding
Combat Arms earplug litigation — 3M's Aearo Technologies subsidiary manufactured military hearing protection; lawsuits from veterans claiming hearing damage resulted in a $6B+ settlement
Post-Solventum restructuring complexity — the separation of 3M's healthcare segment as Solventum introduces one-time restructuring costs, stranded overhead, and revenue loss that complicate near-term financial results

Frequently asked questions

Sterile processing (also called central sterile services or CSSD) is the hospital department that cleans, disinfects, and sterilizes reusable surgical instruments and medical devices after each use before they can be used on the next patient. Surgical instruments (scalpels, forceps, retractors, laparoscopic tools) must be completely sterile to prevent surgical site infections. The sterile processing workflow involves: decontamination (washing instruments to remove blood and debris); inspection and assembly (checking for damage and reassembling instrument sets); packaging (wrapping instrument sets for sterilization); sterilization (typically steam sterilization in autoclaves, or lower-temperature chemical sterilization for heat-sensitive items); and storage and distribution. STERIS's sterilizers, washers, and consumables (sterilization indicators, wrapping materials, detergents) are the primary equipment used throughout this workflow.

Interactive comparison engine

Compare more than two at a time

This page is a fixed writeup on STE and MMM. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.

Up to 5 tickers at once

Add three more names beside STE and MMM, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.

Scoreboard verdict

AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.

Full risk suite

Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.

Correlation heatmap

Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.

Valuation vs profitability

A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.

Holdings overlap and CSV export

For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.

Open STE vs MMM in the engine See what's included

Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

In-Depth Reports

Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.

MMM Report

Related comparisons